Scholarlink

<p>Antimicrobial resistance is a major global health threat, potentially causing 8.22 million deaths annually by 2050. Polymicrobial biofilms significantly contribute to this crisis, leading to treatment failure, especially in chronic airway infections caused by <i>Staphylococcus aureus</i> and <i>Pseudomonas aeruginosa</i>, common in ventilator-associated pneumonia and cystic fibrosis. To address this, we engineered an attenuated <i>Mycoplasma pneumoniae</i> strain, CV8_HAD, to secrete biofilm-disrupting enzymes (PelAh, PslGh, A1-II’ and Dispersin B). CV8_HAD showed strong in vitro activity against single and mixed-species biofilms of <i>S. aureus</i> and <i>P. aeruginosa</i>, and demonstrated in vivo efficacy against <i>S. aureus</i> biofilms in mice and mixed infections in <i>Galleria mellonella</i> larvae. This study establishes engineered <i>M. pneumoniae</i> as a promising therapeutic strategy for tackling microbial biofilms and highlights the potential of G. <i>mellonella</i> larvae models as an alternative to mouse models in advancing research on biofilm-targeting interventions.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Engineered Mycoplasma pneumoniae targeting dual-species bacterial biofilms: a novel strategy against infections

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月17日

查看全文
  • Rocco Mazzolini,
  • Victoria Garrido,
  • Andromeda‑Celeste Gomez,
  • Maria Collantes,
  • Maria Jesús Grilló,
  • Carlos Piñero-Lambea,
  • Isidre Gibert,
  • Daniel Yero,
  • Maria Lluch-Senar

摘要

Antimicrobial resistance is a major global health threat, potentially causing 8.22 million deaths annually by 2050. Polymicrobial biofilms significantly contribute to this crisis, leading to treatment failure, especially in chronic airway infections caused by Staphylococcus aureus and Pseudomonas aeruginosa, common in ventilator-associated pneumonia and cystic fibrosis. To address this, we engineered an attenuated Mycoplasma pneumoniae strain, CV8_HAD, to secrete biofilm-disrupting enzymes (PelAh, PslGh, A1-II’ and Dispersin B). CV8_HAD showed strong in vitro activity against single and mixed-species biofilms of S. aureus and P. aeruginosa, and demonstrated in vivo efficacy against S. aureus biofilms in mice and mixed infections in Galleria mellonella larvae. This study establishes engineered M. pneumoniae as a promising therapeutic strategy for tackling microbial biofilms and highlights the potential of G. mellonella larvae models as an alternative to mouse models in advancing research on biofilm-targeting interventions.